Acadia to replace Independent Bank in S&P 600 at open on 1/3
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 30 2024
0mins
Source: Business Insider
S&P SmallCap 600 Update: Acadia Pharmaceuticals (ACAD) will replace Independent Bank Group (IBTX) in the S&P SmallCap 600 effective January 3, 2025, due to an acquisition of IBTX by SouthState Corp. (SSB).
Acadia Pharmaceuticals News: Recent developments for Acadia include a leadership change with Thomas Garner as Chief Commercial Officer and a price target adjustment from Canaccord.
Analyst Views on ACAD
Wall Street analysts forecast ACAD stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ACAD is 30.24 USD with a low forecast of 21.00 USD and a high forecast of 39.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
18 Analyst Rating
13 Buy
5 Hold
0 Sell
Moderate Buy
Current: 26.530
Low
21.00
Averages
30.24
High
39.00
Current: 26.530
Low
21.00
Averages
30.24
High
39.00
About ACAD
Acadia Pharmaceuticals Inc. is a biopharmaceutical company. It develops and commercializes medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has a portfolio of product candidates and research programs that are designed to address significant unmet medical needs in CNS disorders and rare diseases. Its pipeline includes NUPLAZID (pimavanserin), DAYBUE (trofinetide), ACP-101, ACP-204, and ACP-711. NUPLAZID is a selective serotonin inverse agonist/antagonist preferentially targeting the 5-HT2A receptor. NUPLAZID is developed for the treatment for Parkinson's Disease Psychosis. Trofinetide is a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 designed to treat the core symptoms of Rett syndrome by reducing neuroinflammation and supporting synaptic function. Its early-stage research programs and product candidates include ACP-211, ACP-2591, ACP-271, and Antisense Oligonucleotide (ASO) Programs.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
